1. Home
  2. ESRT vs RZLT Comparison

ESRT vs RZLT Comparison

Compare ESRT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empire State Realty Trust Inc.

ESRT

Empire State Realty Trust Inc.

HOLD

Current Price

$6.93

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$1.81

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESRT
RZLT
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESRT
RZLT
Price
$6.93
$1.81
Analyst Decision
Sell
Strong Buy
Analyst Count
1
6
Target Price
$6.80
$12.33
AVG Volume (30 Days)
1.2M
9.8M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
2.02%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$766,184,000.00
N/A
Revenue This Year
$1.95
N/A
Revenue Next Year
$2.89
N/A
P/E Ratio
$33.83
N/A
Revenue Growth
1.02
N/A
52 Week Low
$6.55
$1.07
52 Week High
$11.29
$11.46

Technical Indicators

Market Signals
Indicator
ESRT
RZLT
Relative Strength Index (RSI) 46.81 22.97
Support Level $6.68 $1.07
Resistance Level $7.09 $11.17
Average True Range (ATR) 0.18 0.66
MACD 0.03 -0.81
Stochastic Oscillator 59.37 7.23

Price Performance

Historical Comparison
ESRT
RZLT

About ESRT Empire State Realty Trust Inc.

Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: